CClinicalTrials.gg
CompletedNCT05739539Updated Jun 24, 2024

Assessment of Retinal Vascular Changes With and Without ILM Peeling in Diabetic Vitrectomy Using OCT-A.

An interventional study of optical coherence tomography angiography and spectral domain optical coherence tomography in Diabetic Vitreous Hemorrhage and Tractional Retinal Detachment, sponsored by Kasr El Aini Hospital. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Kasr El Aini Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Apr 2022, registered Jan 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Tractional retinal detachment (TRD) that involves the macula and non-clearing vitreous hemorrhage are the main causes of permanent vision loss in patients with diabetic retinopathy and requires prompt surgical intervention.

Macular peeling is a surgical technique used in many retinal diseases including diabetic retinal detachment.

Our purpose is to determine whether retinal microcirculatory changes occur after anatomically successful diabetic vitrectomy, and whether changes in blood flow vary if ILM peeling was done and whether changes in macular perfusion affect the final visual outcome.

The aim of this study is to non-invasively evaluate, with optical coherence tomography angiography (OCT-A), the anatomical changes of deep and superficial vascular density in the macula with and without macular peeling in diabetic vitrectomy.

Read the detailed description

Background and Rationale:

Diabetic retinopathy (DR) is a leading cause of blindness among the working age group with increasing numbers of persons being affected worldwide.

The microvascular complications of diabetes result in macular leakage or exudation and vasoproliferative retinal disease, which are the hallmarks of advanced DR. Despite treatment of earlier stages of DR with medical therapy, several eyes will progress to require surgical treatment.

Surgical treatment for the advanced complications of DR can range from removal of a non-clearing vitreous hemorrhage, to more complicated surgical techniques such as in dealing with a combined tractional and rhegmatogenous retinal detachment (TRD/RRD) or tractional retinal detachment (TRD) involving or threatening the macula.

Tractional retinal detachment (TRD) that involves the macula is the main cause of permanent vision loss in patients with diabetic retinopathy and requires prompt surgical intervention. With the small-gauge vitrectomy system, anatomical success rate after pars plana vitrectomy (PPV) is reported to be over 90%.

Macular peeling is a surgical technique used in many retinal diseases including diabetic retinopathy, retinal detachment, macular holes, macular edema or foveal retinoschisis. The technique is based on surgical removal of the preretinal tissue or internal limiting membrane (ILM) in the macula.

PPV with ILM peeling has been reported to reduce retinal edema and improve visual acuity in patients with diabetic macula edema. However there is a controversial whether ILM peeling has benefit in patients undergoing PPV for PDR complications.

Studies found that fewer cases of epiretinal membranes and macular edema were observed postoperatively with ILM peeling in diabetic vitrectomy but visual acuity is similar with and without peeling.

In another recent study evaluating the benefits of ILM peeling in subjects undergoing PPV for the treatment of diabetic vitreous hemorrhage and found that better best-corrected visual acuity, fewer postoperative diabetic macular edema, and a lower incidence of epiretinal membrane at 6 months when ILM peeling was performed.

Optical coherence tomography angiography (OCTA) provides a non-invasive and quantitative approach for investigating retinal and choroidal microvasculature. The retinal vascular plexus of healthy subjects is formed by a superficial plexus located in the ganglion cell layer and nerve fiber layer, and a deep plexus located in the inner nuclear layers . The foveal capillary plexus forms a ring at the margin of the fovea, producing a capillary-free region called the foveal avascular zone (FAZ).

Our purpose is to determine whether retinal microcirculatory changes occur after anatomically successful diabetic vitrectomy, and whether changes in blood flow vary if ILM peeling was done and whether changes in macular perfusion affect the final visual outcome.

The aim of this study is to non-invasively evaluate, with optical coherence tomography angiography (OCT-A), the anatomical changes of deep and superficial vascular density in the macula with and without macular peeling in diabetic vitrectomy.

To our knowledge, there are presently no any studies evaluating OCT-A retinal vascular changes with and without ILM peeling after diabetic vitrectomy.

Objectives:

To assess the OCT-A retinal vascular changes with and without ILM peeling in diabetic vitrectomy patients.

  • Methodology in details:

This prospective study will be conducted at Kasr Al-Aini Ophthalmology department and will include PDR patients who are candidates for PPV which will be recruited and assessed for eligibility for inclusion according to the above criteria.

All participants will be subjected to the following:

  • Written informed consent.
  • Detailed history including duration of diabetes, its treatment and glycemic control and systemic hypertension.
  • History of ocular trauma, previous ocular surgery, history of treatment with intravitreal anti-VEGF or Argon retinal photocoagulation.
  • Complete ophthalmic examination including best corrected visual acuity measurement, intraocular pressure, slit lamp examination and fundus examination.
  • Pre-operative OCT-Angiography if possible in patients having clear media.
  • Patients who are candidates for PPV will be assigned randomly using simple randomization with Microsoft Excel into one of two groups:

    • Group A: PPV with ILM peeling.
    • Group B: PPV without ILM peeling.
  • 23-gauge PPV will be performed for patients in both groups , infusion pressure will be between 25-30 mmHg and in case of need to increase pressure for bleeding it will be less than 60 mmHg for no more than 5 minutes.
  • Phacoemulsification \& PCIOL will be done for cases with significant cataract.
  • Silicone oil tamponade 1000 csk will be used for all cases. Follow up of the patients at 3 and 6 months after surgery with measuring BCVA, fundus examination, OCT-Angiography (optovue Inc) scan area of 3x3 mm and 6x6 mm to detect vascualr density: superficial capillary plexus (SCP), deep capillary plexus (DCP), foveal and parafoveal all quadrants using ETDRS circles, and the foveal avascular zone (FAZ) area and acirculatory index.
  • OCT for measuring central macular thickness \& ganglion cell complex (GCC) will be done.
  • Patients' serial numbers only will be used on data collection sheets. Data will be entered on a computer with access limited to the researchers in order to ensure confidentiality of patients' information.

    • Intervention:
    • Therapeutic intervention (please describe):
    • Pars plana vitrectomy (PPV) will be performed for diabetic patients who meet the inclusion criteria, in group A: ILM peeling will be done and in group B: PPV without ILM peeling.
    • Diagnostic intervention (please describe):
    • OCT-A (optovue Inc) and OCT for measuring ganglion cell complex (GCC) will be done 3 and 6 months following surgery comparing both groups.
    • Does the research involve? Human participants
    • Type of consent of study participants:

Written consent

  • Potential risks:

    • Iatrogenic Retinal break.
    • Infection.
    • Elevated intraocular pressure.
  • Confidentiality of data:

None of the data obtained during the study will contain any personal information that can lead to patient identification, no personal photos for the patients will be obtained, no names or patients' identification numbers or records will be displayed.

Sample size (number of study subjects included and justification including the clinical and statistical assumptions supporting sample size calculation)

Total number of 36 eyes to be divided equally in 2 groups:

  • Group A: 18 eyes will undergo PPV with ILM peeling.
  • Group B: : 18 eyes will undergo PPV without ILM peeling.

Assuming equal number of eyes in two groups, power of study of 80%, statistical significance alpha of 0.05 (two sided). Based on data from literature [13] calculating minimal sample size needed to compare macular vascular density changes between two groups of diabetic vitrectomy with and without ILM peeling to detect difference of 3 % in vascular density with SD of 3 % using the following equation:

n= (2) (3) 2 (2.8) 2 / (3) 2 = 16 in each group

Assuming 10 % drop-out of cases the total number of cases will be 36 eyes.

Sampling technique: A convenient sample of patients with the inclusion and exclusion criteria will be assigned into study till reaching total sample size calculated.

Statistical analysis Data analysis packages will be SPSS version 21 Qualitative data will be presented by number and percentage , quantitative data will be presented by mean, standard deviation, median and interquartile range . Parametric and non-parametric tests of significant will be done chi square, Fisher exact for non-parametric data and student t test and ANOVA test for parametric data, man whitney test and mcnemar test for non parameteric data, Level of significance was set at p-value equal to or below 0.05.

Source of funding: (Please include source of funding even if self funding) Self funding

02

Conditions studied

  • Diabetic Vitreous Hemorrhage
  • Tractional Retinal Detachment
03

In context

Retinal Detachment

207 studies on the registry are indexed under Retinal Detachment; 27 are open to participants now.

This study's enrollment of 36 is below the median of 50 across 136 interventional studies indexed under Retinal Detachment.

Browse Retinal Detachment studies →

Lead sponsor

Kasr El Aini Hospital is the lead sponsor of 273 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age above 18 years old of both sexes.
  • Patients having diabetic tractional retinal detachement threatening the macula (traction over posterior pole with attached fovea).
  • Combined tractional-rhegmatogenous retinal detachement with attached macula.
  • Diabetic persistent fibrovascular proliferation not responding to panretinal photocoagulation.
  • Non clearing diabetic vitreous hemorrhage, subhyaloid hemorrhage.

Exclusion criteria

Exclusion Criteria:

  • Subject has had a previous vitrectomy (anterior or PPV) in the study eye.
  • Subject has uncontrolled neovascular glaucoma (intraocular pressure > 30 mmHg despite medical/surgical treatment) in the study eye.
  • Previous history of trauma in the study eye.
  • Previous history of Anti-VEGF injection.
  • Tractional macular detachment.
  • Coexisting macular hole.
  • Cases with previous arterial or venous occlusions.
  • Coexisting posterior segment inflammation.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    pars plana vitrectomy with ILM peeling

    Diabetic patients who fulfill the inclusion critera and will undergo pars plana vitrectomy and ILM peeling

    Diagnostic Test: optical coherence tomography angiography · Diagnostic Test: spectral domain optical coherence tomography

  • Active comparator
    pars plana vitrectomy without ILM peeling

    Diabetic patients who fulfill the inclusion critera and will undergo pars plana vitrectomy without ILM peeling

    Diagnostic Test: optical coherence tomography angiography · Diagnostic Test: spectral domain optical coherence tomography

Interventions

  • Diagnostic testoptical coherence tomography angiography

    optical coherence tomography angiography will be done postoperatively in both groups to assess the retinal microvascular changes

  • Diagnostic testspectral domain optical coherence tomography

    optical coherence tomography for ganglion cell complex (GCC) measurement and assessment of macular edema or epiretinal membrane formation will be done postoperatively in both groups

06

What researchers measure

Primary outcomes

  1. Compare the superficial and deep vascular densities using OCT-A with and without ILM peeling in diabetic vitrectomy patients.

    Compare the superficial and deep vascular densities in percentage compared to normative database using OCT-A (Optovue) with and without ILM peeling in diabetic vitrectomy patients.

    Time frame: 18 months total study duration , 9 months follow up

  2. Compare the foveal avascular zone using OCT-A between both groups.

    Compare the foveal avascular zone measured in micrometer using OCT-A between both groups.

    Time frame: 18 months total study duration , 9 months follow up

Secondary outcomes

  1. Compare the best corrected visual acuity in both groups

    Compare the best corrected visual acuity in both groups using decimal numbers on snellen's chart

    Time frame: 18 months total study duration , 9 months follow up

  2. Compare OCT ganglion cell complex (GCC) changes in both groups.

    Compare OCT ganglion cell complex (GCC) changes in both groups measured as percentage of loss compared to age related normative database on the OCT device.

    Time frame: 18 months total study duration , 9 months follow up

  3. Compare incidence of epiretinal membrane formation in both groups.

    Compare incidence of epiretinal membrane formation in both groups using OCT device either present or absent.

    Time frame: 18 months total study duration , 9 months follow up

  4. Compare incidence of macular edema in both groups.

    Compare incidence of macular edema in both groups measured by calculating the central foveal thickness in micrometers using the OCT device

    Time frame: 18 months total study duration , 9 months follow up

07

Study locations

1 site
  • KasrAlaini hospital
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05739539
Lead sponsor
Kasr El Aini Hospital
Responsible party
Ahmed Essam Faseeh (Assistant Lecturer of Ophthalmology, Kasr El Aini Hospital) — Principal investigator
First posted
Feb 22, 2023
Start date
Apr 1, 2022
Primary completion
Dec 20, 2023
Completion
Jan 5, 2024
Last update
Jun 24, 2024

Study contacts

Ahmed E Faseeh, MSc
principal investigator · KasrAlaini hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion